I expect ACW to provide ongoing news about multiple new targeted...

I expect ACW to provide ongoing news about multiple new targeted indications, independent associated cortisol research results, partnerships with researchers and big pharma, and recruitment progress into next year, keeping the SP up while continuing momentum and interest until the earliest results are released.
I suspect the world markets over the next year, both stock and commerce, will be significantly diminished by major supply channel issues, China issues, Covid issues, lessening optimism and growing instability. My safe haven to avoid the coming havoc is Actinogen, which will ultimately rise or fall on its medical leadership and on its merits and potential as a blockbuster multi-target drug that can change the dynamics of treatment for many conditions. As I have said before, there is always substantial risk in early stage small pharma, but the reward in this case can be great and the benefit to human health outstanding. Cheers & GLTA